• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Rivaroxaban associated with significantly increased risk of major ischemic or hemorrhagic events versus apixaban in patients with atrial fibrillation

byYuchen DaiandMichael Pratte
December 22, 2021
in Cardiology, Chronic Disease, Emergency, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In patients with atrial fibrillation over 65, treatment with rivaroxaban compared to apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.

2. Patients receiving reduced doses of anticoagulants had increased relative and absolute risk of major ischemic or hemorrhagic events.

Evidence Rating Level: 2 (Good)

Study Rundown: Direct oral anticoagulants such as rivaroxaban and apixaban are the preferred anticoagulants for ischemic stroke prevention in patients with atrial fibrillation However, their comparative efficacy is unknown. This cohort study compared major ischemic and hemorrhagic outcomes in patients with atrial fibrillation who initiated anticoagulation treatment with rivaroxaban or apixaban. The primary endpoint was a composite of major ischemic (stroke/systemic embolism) and hemorrhagic (intracerebral hemorrhage/other intracranial bleeding/fatal extracranial bleeding) events. Secondary endpoints were nonfatal extracranial bleeding and total mortality (fatal ischemic/hemorrhagic event or other death during follow-up). Among 581,451 Medicare beneficiaries aged 65 or older with atrial fibrillation, the adjusted incidence of major ischemic or hemorrhagic events for rivaroxaban and apixaban was 16.1 vs 13.4 per 1,000 person-years respectively, a statistically significant difference. These results suggested that treatment with rivaroxaban compared to apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events in patients with atrial fibrillation. A limitation of this study was that a substantial proportion of patients discontinued treatment for reasons unrelated to the safety profile of anticoagulants, resulting in potential confounding of the results.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Trends and variation in oral anticoagulant choice in patients with atrial fibrillation

RELATED REPORTS

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

In-Depth [retrospective cohort]: This cohort study included 581,451 patients (mean age, 77.0 years; 291,966 [50.2%] women) with atrial fibrillation on rivaroxaban (n = 227,572) or apixaban (n = 353,879) treatment, where 134,393 (23.1%) patients received reduced doses. Patients were followed for up to 4 years between January 2013 to November 2018, for a total of 474,605 person-years of follow-up (median [IQR], 174 [62-397] days). Overall, the adjusted primary outcome rate for rivaroxaban vs apixaban was 16.1 vs 13,4 per 1,000 person-years respectively (RD, 2.7 [95%CI, 1.9-3.5]; HR, 1.18 [95%CI, 1.12-1.24]). Patients on rivaroxaban had increased risk for both major ischemic events (8.6 vs 7.6 per 1,000 person-years; RD, 1.1 [95%CI, 0.5-1.7]; HR, 1.12 [95%CI, 1.04-1.20]) and hemorrhagic events (7.5 vs 5.9 per 1,000 person-years; RD, 1.6 [95%CI, 1.1-2.1]; HR, 1.26 [95% CI, 1.16-1.36]), including fatal extracranial bleeding (1.4 vs 1.0 per 1,000 person-years; RD, 0.4 [95%CI, 0.2-0.7]; HR, 1.41 [95%CI, 1.18-1.70]). The rivaroxaban group had increased risk of nonfatal extracranial bleeding (39.7 vs 18.5 per 1,000 person-years; RD, 21.1 [95%CI, 20.0-22.3]; HR, 2.07 [95%CI, 1.99-2.15]), fatal ischemic/hemorrhagic events (4.5 vs 3.3 per 1000 person-years; RD, 1.2 [95%CI, 0.8-1.6]; HR, 1.34 [95%CI, 1.21-1.48]), and total mortality (44.2 vs 41.0 per 1,000 person-years; RD, 3.1 [95%CI, 1.8-4.5]; HR, 1.06 [95%CI, 1.02-1.09]). Lastly, patients receiving both the reduced dose (27.4 vs 21.0 per 1,000 person-years; RD, 6.4 [95%CI, 4.1-8.7]; HR, 1.28 [95%CI, 1.16-1.40]) and the standard dose (13.2 vs 11.4 per 1,000 person-years; RD, 1.8 [95%CI, 1.0-2.6]; HR, 1.13 [95%CI, 1.06-1.21]) of rivaroxaban had increased risk of the primary outcome.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulantanticoagulationapixabanatrial fibrillationrivaroxaban
Previous Post

#VisualAbstract: Neoadjuvant chemotherapy plus surgery improves overall survival compared to surgery alone in locally advanced esophageal cancer

Next Post

Omega-3 fatty acid supplements did not reduce depression risk in adults compared to placebo

RelatedReports

Intensive rehabilitation not superior to traditional therapy for arm function after stroke
Cardiology

Left atrial reservoir strain improves ischemic stroke risk prediction in low-risk patients

January 31, 2023
#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation
StudyGraphics

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

January 17, 2023
Patient Basics: Atrial Fibrillation
Cardiology

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

January 16, 2023
Propofol appears safe and effective in procedural sedation for cardioversion
Chronic Disease

The Apple Watch may have future applications in mental health disorders

December 12, 2022
Next Post
Higher omega-3 blood levels associated with larger brain volumes

Omega-3 fatty acid supplements did not reduce depression risk in adults compared to placebo

#VisualAbstract: Pericardiotomy after cardiac surgery may reduce the incidence of postoperative atrial fibrillation

#VisualAbstract: The use of COVID-19 convalescent plasma not beneficial to patients hospitalized with COVID-19

Ultrasound enhances gastrointestinal absorption of drugs at low frequencies

Wellness Check: Addictions

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Evaluation of medical school parental leave policies in the United States
  • Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer
  • Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options